Search

Realization of the full potential of single‐atom photoelectrocatalysts in sustainable energy generation requires careful consideration of the design of the host material. Here, a comprehensive methodology for the rational design of photoelectrocatalysts using anodic titanium dioxide (TiO2) nanofilm as a model platform is presented. The properties of these nanofilms are precisely engineered to elucidate synergies across structural, chemical, optoelectronic, and electrochemical properties to maximize the efficiency of the hydrogen evolution reaction (HER). These findings clearly demonstrate that thicker TiO2 nanofilms in anatase phase with pits on the surface can accommodate single‐atom platinum catalysts in an optimal configuration to increase HER performance. It is also evident that the electrolyte temperature can further enhance HER output through thermochemical effect. A judicious design incorporating all these factors into one system gives rise to a ten‐fold HER enhancement. However, the reusability of the host photoelectrocatalyst is limited by the leaching of the Pt atom, worsening HER. Density‐functional theory calculations have provided insights into the mechanism underlying the experimental observations in terms of moderate hydrogen adsorption and enhanced gas generation. This improved understanding of the critical factors determining HER performance in a model photoelectrocatalyst paves the way for future advances in scalable and translatable photoelectrocatalyst technologies. [ABSTRACT FROM AUTHOR]

In this study, nanoporous anodic alumina distributed‐Bragg reflectors (NAA–DBRs) functionalized with tungsten trioxide (WO3) are used as prototype photoelectrocatalysts (PEC) for harnessing the slow photon effect to maximize photon‐to‐electron conversion efficiency under UV–visible–NIR illumination. NAA–DBR structures are structurally engineered by anodization, where their characteristic photonic stopband is precisely tuned along specific positions of the UV–visible spectrum. Subsequent atomic layer deposition is employed to coat the inner surface of these porous structures with WO3 semiconductor layers. Upon the application of overpotential bias, these platforms reveal excellent electron–hole pair separation to boost photoelectrocatalytic reactions. Photoelectrochemical degradation of methylene blue is used as a model reaction to elucidate enhancements associated with structural and optoelectronic arrangements. Notably, precise spectral alignment between the photonic stopband's red edge and the absorbance band of methylene blue enhances the degradation performance through the slow photon effect. Applying an overpotential bias further improves the photodegradation performance through efficient charge separation. These systems outperform comparable structures in this model reaction, achieving a maximum kinetic rate of 13.7 ± 2.0 h−1. The findings create new opportunities to develop high‐performing PEC technologies harnessing light–matter interactions. [ABSTRACT FROM AUTHOR]

A series of β‐strand peptides comprising redox‐active amino acids in the P2 position were synthesized to investigate the effects of electron‐rich side chains on charge transfer and possible coupling interactions between side chains. Electrochemical results indicated a direct link between aromaticity of the side chains and electron transfer rate constants, while single‐molecule conductance studies supported the ability of the electron‐rich side chains to behave as 'stepping stones' to facilitate electron transfer through the peptides. Additional electrochemical analysis of the analogue containing D‐Tyr in the P2 position was undertaken at various pH levels and revealed intramolecular coupling interaction between the side chains, providing further insights on proton coupled electron transfer (PCET). These findings progress the established fundamental knowledge of charge transfer kinetics and explore new pathways for advancement in the architecture of molecular‐based electronic components and devices. [ABSTRACT FROM AUTHOR]

Neuroimmune signaling is a key process underlying neuropathic pain. Clinical studies have demonstrated that 18 kDa translocator protein (TSPO), a putative marker of neuroinflammation, is upregulated in discrete brain regions of patients with chronic pain. However, no preclinical studies have investigated TSPO dynamics in the brain in the context of neuropathic pain and in response to analgesic treatments. We used positron emission tomography-computed tomography (PET-CT) and [ 18 F]-PBR06 radioligand to measure TSPO levels in the brain across time after chronic constriction injury (CCI) of the sciatic nerve in both male and female rats. Up to 10 weeks post-CCI, TSPO expression was increased in discrete brain regions, including medial prefrontal cortex, somatosensory cortex, insular cortex, anterior cingulate cortex, motor cortex, ventral tegmental area, amygdala, midbrain, pons, medulla, and nucleus accumbens. TSPO was broadly upregulated across these regions at 4 weeks post CCI in males, and 10 weeks in females, though there were regional differences between the sexes. Using immunohistochemistry, we confirmed TSPO expression in these regions. We further demonstrated that TSPO was upregulated principally in microglia in the nucleus accumbens core, and astrocytes and endothelial cells in the nucleus accumbens shell. Finally, we tested whether TSPO upregulation was sensitive to diroximel fumarate, a drug that induces endogenous antioxidants via nuclear factor E2-related factor 2 (Nrf2). Diroximel fumarate alleviated neuropathic pain and reduced TSPO upregulation. Our findings indicate that TSPO is upregulated over the course of neuropathic pain development and is resolved by an antinociceptive intervention in animals with peripheral nerve injury., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

While cancer survivorship has increased due to advances in treatments, chemotherapy often carries long-lived neurotoxic side effects which reduce quality of life. Commonly affected domains include memory, executive function, attention, processing speed and sensorimotor function, colloquially known as chemotherapy-induced cognitive impairment (CICI) or "chemobrain". Oxidative stress and neuroimmune signaling in the brain have been mechanistically linked to the deleterious effects of chemotherapy on cognition and sensorimotor function. With this in mind, we tested if activation of the master regulator of antioxidant response nuclear factor E2-related factor 2 (Nrf2) alleviates cognitive and sensorimotor impairments induced by doxorubicin. The FDA-approved systemic Nrf2 activator, diroximel fumarate (DRF) was used, along with our recently developed prodrug 1c which has the advantage of specifically releasing monomethyl fumarate at sites of oxidative stress. DRF and 1c both reversed doxorubicin-induced deficits in executive function, spatial and working memory, as well as decrements in fine motor coordination and grip strength, across both male and female mice. Both treatments reversed doxorubicin-induced loss of synaptic proteins and microglia phenotypic transition in the hippocampus. Doxorubicin-induced myelin damage in the corpus callosum was reversed by both Nrf2 activators. These results demonstrate the therapeutic potential of Nrf2 activators to reverse doxorubicin-induced cognitive impairments, motor incoordination, and associated structural and phenotypic changes in the brain. The localized release of monomethyl fumarate by 1c has the potential to diminish unwanted effects of fumarates while retaining efficacy.